MedTrace Logo

Galactose Supplementation for the Treatment of MOGHE

NCT04833322 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-04-06

No results posted yet for this study

Summary

Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is a new entity frequently associated with refractory epilepsy and neurodevelopmental disorders. Recently, it has been associated to SLC35A2 (Solute Carrier Family 35 Member A2) brain mosaic pathogenic variants. In addition, patients with germline SLC35A2 pathogenic variants improve with galactose supplementation. Therefore, the investigators aim to elucidate whether d-galactose as an add-on treatment might improve epilepsy and developmental outcomes in patients with MOGHE.

Conditions

  • Refractory Epilepsy
  • SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation

Interventions

DIETARY_SUPPLEMENT

D-Galactose

Galactose supplementation, once per day, up to 1.5g/kg per day

Sponsors & Collaborators

  • Hospital Ruber Internacional

    lead OTHER

Principal Investigators

  • Angel Aledo-Serrano, MD, PhD · Hospital Ruber Internacional

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-15
Primary Completion
2021-09-01
Completion
2021-10-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04833322 on ClinicalTrials.gov